Liquidia to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will participate in two upcoming investor conferences: the BTIG Biotechnology Conference 2022 on August 8 in New York, featuring CFO Michael Kaseta's live Fireside Chat at 2:00 p.m., and the Wedbush PacGrow 2022 Healthcare Conference on August 9, a virtual event. The biopharmaceutical firm specializes in pulmonary hypertension treatments, including its product YUTREPIA™ (treprostinil) inhalation powder. More details can be found at www.liquidia.com.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was +1.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week:
BTIG Biotechnology Conference 2022
Date: Monday, August 8, 2022
Location: Hybrid Event at St. Regis Hotel, New York, New York
Chief Financial Officer Michael Kaseta will also participate in a live Fireside Chat at 2:00 p.m. To listen to the event, please contact your BTIG representative with interest.
Wedbush PacGrow 2022 Healthcare Conference
Date: Tuesday, August 9, 2022
Location: Virtual Event
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.